IL127166A0 - Type-2 chemokine binding proteins and methods of use therefor - Google Patents

Type-2 chemokine binding proteins and methods of use therefor

Info

Publication number
IL127166A0
IL127166A0 IL12716697A IL12716697A IL127166A0 IL 127166 A0 IL127166 A0 IL 127166A0 IL 12716697 A IL12716697 A IL 12716697A IL 12716697 A IL12716697 A IL 12716697A IL 127166 A0 IL127166 A0 IL 127166A0
Authority
IL
Israel
Prior art keywords
type
chemokine binding
methods
binding proteins
use therefor
Prior art date
Application number
IL12716697A
Other languages
English (en)
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of IL127166A0 publication Critical patent/IL127166A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Catalysts (AREA)
IL12716697A 1996-05-22 1997-05-21 Type-2 chemokine binding proteins and methods of use therefor IL127166A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1813796P 1996-05-22 1996-05-22
PCT/US1997/008590 WO1997044054A2 (fr) 1996-05-22 1997-05-21 Proteines de fixation de la chimiokine de type 2 et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
IL127166A0 true IL127166A0 (en) 1999-09-22

Family

ID=21786445

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12716697A IL127166A0 (en) 1996-05-22 1997-05-21 Type-2 chemokine binding proteins and methods of use therefor

Country Status (21)

Country Link
EP (1) EP0901379B1 (fr)
JP (1) JP2000511535A (fr)
KR (1) KR20000015895A (fr)
CN (1) CN1226171A (fr)
AT (1) ATE196091T1 (fr)
AU (1) AU3136197A (fr)
BR (1) BR9710028A (fr)
CA (1) CA2256568A1 (fr)
CZ (1) CZ378998A3 (fr)
DE (1) DE69703040T2 (fr)
DK (1) DK0901379T3 (fr)
ES (1) ES2152095T3 (fr)
GR (1) GR3034805T3 (fr)
HK (1) HK1017622A1 (fr)
IL (1) IL127166A0 (fr)
NO (1) NO985412L (fr)
NZ (1) NZ333456A (fr)
PL (1) PL330149A1 (fr)
PT (1) PT901379E (fr)
TR (1) TR199802392T2 (fr)
WO (1) WO1997044054A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
GB9916703D0 (en) * 1999-07-16 1999-09-15 Alcami Antonio Viral protein binding compositions and methods
AU2001261738A1 (en) * 2000-05-17 2001-11-26 London Health Sciences Centre Compositions and methods for promoting immunosuppression
JP2004508338A (ja) 2000-09-08 2004-03-18 グリフォン　セラピューティクス，インコーポレーテッド ポリマー修飾合成タンパク質
US6894155B2 (en) 2000-10-11 2005-05-17 Viron Therapeutics Nucleic acid molecules and polypeptides for immune modulation
DK1339737T3 (da) 2000-12-04 2007-10-15 Viron Therapeutics Inc Immunomodulatorisk protein dannet ud fra Yaba-abetumorvirus
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
DE10162869A1 (de) * 2001-12-20 2003-07-31 Alexander Cherkasky Invasive lineare halb-zyklische und zyklische Systeme zur Herauslockung der Krankheitserreger
GB0304531D0 (en) * 2003-02-27 2003-04-02 Isis Innovation Treatment
JP4768620B2 (ja) * 2003-05-15 2011-09-07 ジェネンテック， インコーポレイテッド 敗血症の予防及び治療のための方法及び組成物
PL1663197T3 (pl) 2003-09-09 2008-09-30 Biogen Idec Int Gmbh Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy
EP4137819A1 (fr) 2007-02-08 2023-02-22 Biogen MA Inc. Compositions et leurs utilisations pour le traitement de la sclérose en plaques
CN113234137B (zh) * 2021-06-21 2022-02-25 华中农业大学 分离自草鱼的CXCL20a蛋白在作为抗菌肽中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604418B1 (fr) * 1991-03-29 1998-09-23 Immunex Corporation Antagonistes de cytokines a base de proteines virales isolees
AU718049B2 (en) * 1995-04-19 2000-04-06 Viron Therapeutics, Inc. Chemokine binding protein and methods of use therefor
EP0862449A4 (fr) * 1995-09-29 1998-11-11 Immunex Corp Inhibiteur de la chemokine

Also Published As

Publication number Publication date
CN1226171A (zh) 1999-08-18
WO1997044054A2 (fr) 1997-11-27
EP0901379A2 (fr) 1999-03-17
DK0901379T3 (da) 2000-12-27
AU3136197A (en) 1997-12-09
NO985412D0 (no) 1998-11-20
GR3034805T3 (en) 2001-02-28
WO1997044054A3 (fr) 1998-05-14
ATE196091T1 (de) 2000-09-15
DE69703040D1 (de) 2000-10-12
TR199802392T2 (xx) 1999-02-22
NO985412L (no) 1999-01-20
BR9710028A (pt) 1999-08-10
NZ333456A (en) 2000-08-25
DE69703040T2 (de) 2001-05-03
CA2256568A1 (fr) 1997-11-27
KR20000015895A (ko) 2000-03-15
PT901379E (pt) 2001-02-28
JP2000511535A (ja) 2000-09-05
CZ378998A3 (cs) 1999-07-14
HK1017622A1 (en) 1999-11-26
ES2152095T3 (es) 2001-01-16
PL330149A1 (en) 1999-04-26
EP0901379B1 (fr) 2000-09-06

Similar Documents

Publication Publication Date Title
WO1996033730A3 (fr) Proteine de liaison a la chemokine et ses procedes d'utilisation
IL127166A0 (en) Type-2 chemokine binding proteins and methods of use therefor
EP1674477A3 (fr) Polypeptides de liaison pour la protéine stimulatrice des lymphocytes B (BLyS)
IL161016A (en) Polypeptides capable of ang-2 binding
WO2002032925A3 (fr) Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison
WO1999024463A3 (fr) Proteines contenant une sequence signal
BR0009206A (pt) Isolamento e análise de proteina
DE69833014D1 (de) Menschliche toll homologen
AU8812498A (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
AU4367196A (en) Novel protein domain which binds tyrosine phosphorylated proteins
WO1998057983A3 (fr) Proteine de mammifere de type facteur de croissance nerveuse
WO1997044451A3 (fr) Molecules de liaison d'amines vasoactives
DK1387854T3 (da) SFRP og peptidmotiver som interagerer med SFRP og fremgangsmåder til anvendelse deraf
DK0968288T3 (da) z219a, en human homolog til 2-19 protein
WO1998024896A3 (fr) Muteines de la proteine de l'obesite
AU6017996A (en) P-53 binding protein called mdmx and encoding sequences for said protein
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
WO2001090183A3 (fr) Proteine humaine secretee zsig47
DK0999849T3 (da) Anvendelse af LBP til sepsisbehandling
MX9701904A (es) Proteinas de enlace de pka novedosas y usos de las mismas.